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from 1-11 months post transplant. Favorable engraftment and
survival was seen as compared to a control group from the COBLT
study. The cummulative incidence of neutrophil engraftment by
day 42 (median  17 days) and platelet engraftment by day 100
(median 50 days) were 90.9% (95% CI 78-100) [p0.001) and
79.5% (95% CI 63.6-95.5%) [p0.003]. Overall survival at 180
days was 92.8% (95% CI 63.6-95.5) [p0.001]. CD4 recovery was
accelerated. Isolation and priming of ALDHbr cells is feasible and
safe. Favorable effects on engraftment and survival were observed.
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VALIDATION STUDY OF MONONUCLEAR CELL RECOVERY USING THE
AXP AUTOXPRESS PLATFORM
Li, J.1, Zhu, H.1, Nguyen, M.1, Emmanuel, P.1, Baker, B.1, Marr, D.1,
Weatherford, C.1, Chapman, J.1 1Thermogenesis Co., Rancho Cordova,
CA.
BACKGROUND: The AXP AutoXpress Platform has been
developed for automatically processing cord blood stem cells be-
fore cryopreservation. The platform consists of a microprocessor-
controlled device, docking station, functionally closed sterile dis-
posable bag set and supporting XpressTRAK™ software. Cord
blood is sterilely transferred to the bag set and centrifuged in the
device at high and low speeds. During the high speed spin, the cells
separate into layers according to density and during the low speed
spin the device transfers the red blood cells (RBC) into the RBC
bag, mononuclear cells (MNC) into the freezing bag and retains
the plasma in the processing/plasma bag. The MNC volume in the
freezing bag is operator selected and achieved with an analytical
balance built into the AXP device. After being mixed with 5 ml
cryoprotectant, the 25 ml MNC solution in the freezing bag can be
directly frozen at a controlled rate and stored in the robotic
BioArchive® System.
STUDY DESIGN: The validation study was designed and per-
formed to determine the efﬁciency of MNC recovery with and
without addition of 20% HES before processing. High speed
centrifugation was 1400xg for 20 minutes and low speed spin 80xg
for 10 or 20 min. Human peripheral blood was used in the study to
serve as a surrogate for cord blood. Blood volumes investigated
were 60, 120 and 170 ml. In addition to MNC recovery, other
parameters such as WBC recovery, red cell reduction, hematocrit,
ﬁnal volume in the freezing bag, and cell mass balance in the
freezing, RBC and processing bags were also measured.
RESULTS: Results are presented as the mean  S.D. for MNC
recovery value. The following table summarizes MNC cell recov-
ery from human peripheral blood in the freezing bag with 60, 120
and 170 ml of initial blood volume in the presence or absence of
20% HES.
CONCLUSION: The AXP AutoXpress Platform consistently
yields MNC recovery greater than 90% with processing blood
volume at 60 and 120 ml without HES addition. Adding 20% HES
remarkably enhances average MNC recovery to greater than 90%
when blood volume processed is 170 ml. The results from this
study demonstrate that the AXP AutoXpress Platform can achieve
automated volume reduction of blood with high efﬁciency of
MNC recovery.
N
Low
speed
centrifuge
Volumes
(mL)
MNC
recovery
(%)
HES
addition
12 80xg, 20min 60 91.5  4.8 20% HES
12 80xg, 20min 170 92.3  5.4 20% HES
8 80xg, 10min 60 96.0  6.0 20% HES
8 80xg, 10min 170 98.7  5.4 20% HES
8 80xg, 10min 60 98  5 no HES
8 80xg, 10min 120 92  14 no HES
8 80xg, 10min 170 78  15 no HES
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A COMPARISON OF THE TRADITIONAL WATER-BATH VS. DRY THAW-
ING METHOD FOR THAWING CRYOPRESERVED PERIPHERAL STEM
CELL COMPONENTS WITH A GOAL OF REDUCING THE CONTAMINA-
TION RISKS
Merkel, D.1, Trieu, K.1 1University of Kansas Hospital, Kansas City,
KS.
The thawing of cryopreserved products has traditionally been
done using a water-bath. The potential contamination risks in-
volved with thawing cryopreserved stem cell products are always a
concern. A safer, more standardized method of thawing cryopre-
served products while reducing the contamination risk associated
with water-baths was investigated. A comparison study was per-
formed using the Equitherm Model 299-733 water-bath and the
Cytotherm® Model D1 Dry Plasma Thawing unit. Two equivalent
cryopreserved bags from each of nine peripheral stem cell collec-
tions were thawed using both water-bath and dry thawing meth-
ods. Bag volumes, storage, cell concentrations, initial product tem-
perature and initial equipment temperature were identical.
Measured parameters included post-thaw cell viability, product
temperature, Lactate Dehydrogenase (LDH) levels and tempera-
ture recovery time of the equipment. All products were placed into
an over-wrap bag. Viabilities found using each method were un-
remarkable with a variation range of less than 5% and an average
variation of less than 1%. The differences noted were: 1) the
products thawed in the water-bath had a temperature range of
–2.0°C to 24.4°C post-thaw versus a temperature range of 6.0°C to
13.6°C following dry thawing method, 2) LDH levels of products
thawed in the water-bath had LDH levels averaging 37.5% higher
with a range of 5.8% to 87.8% higher than dry thawing method, 3)
temperature recovery of the water-bath to desired temperature
averaged 8.9 minutes compared to 4 minutes using the dry thawing
unit. After performing this comparison, it was observed that the
dry thawing method may have beneﬁts over the traditional water-
bath method. The beneﬁts of the dry thawing method include: 1)
the reduced risk of product contamination, 2) lower LDH levels on
the thawed products which may indicate less cell destruction or
lysis, 3) a consistent post-thaw temperature of the product ensuring
that the product is not over-warmed or under-thawed, 4) faster
temperature recovery of the equipment following each thaw allow-
ing for a consistent starting temperature when performing multiple
thaws, 5) elimination of the need to hand manipulate the product
during the thawing process, 6) lastly, the dry thawing unit was very
portable with no water to maintain.
112
RIGOROUS PROTOCOLS USING ALEMTUZUMAB TO T CELL DEPLETE
STEM CELL PRODUCTS
Talmadge, J.E.1, Gulen, D.1, Bociek, R.G.1 1University of Nebraska
Medical Center, Omaha, NE.
The therapeutic effect of allogeneic peripheral stem cell trans-
plantation (alloPSCT) is related to an immune-mediated graft-
versus-tumor (GVT) effect. However, alloPSCT is limited by
T-cell mediated graft-versus-host disease(GVHD). Approaches
used to treat or prevent GVHD include in vitro or in vivo purging
of T cells using monoclonal antibodies such as Alemtuzumab,
which is directed against CD52 on B and T lymphocytes, mono-
cytes, and some dendritic cells (DCs). Alemtuzumab has been
injected systemically to treat established GVHD, and ex vivo to
purge T cells from stem cell products (SCPs) to reduce GVHD
induction. T-cell depletion with Alemtuzumab infusion is an ef-
fective method to treat GVHD but is also associated with relapse
and infectious disease. Ex vivo purging by the addition Alemtu-
zumab to a SCP, shaking for 15 minutes and infusion is also
effective. However, the efﬁcacy of this T cell purging protocol can
not be assessed and potentially results Alemtuzumab infusion. The
present study examined the effect of Alemtuzumab co-incubation
on cellular subsets and the mechanism of purging i.e. antibody
dependant cellular cytotoxicity (ADCC) vs. antibody-complement
toxicity. Our studies revealed that cellular concentration is critical
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to purging activity, such that high cellularity (10e8 cells/ml) results
in a signiﬁcant loss (65%) of T and B cells with only 1 hr co-
incubation, raising to 85-90% at a 6 hr co-incubation. Co-incuba-
tion at a log lower cellularity results in a 20-30% T-cell loss.
ADCC is the primary purging mechanism; however, serum is
required to retain cellular viability as is DNAse to reduce cellular
clumping. Co-incubation temperature has little effect on purging,
although cellular viability is higher at 4C compared to 37C. T, B
and NK cells are sensitive to Alemtuzumab ADCC. DCs have a
lower sensitivity and there is a differential sensitivity of DC subsets
to alemtuzumab-mediated ADCC, such that CD123 DCs have a
lower sensitivity as compared to the CD11c DCs. Further, im-
mature myeloid suppressor cells (IMSCs) that are Lin-DR-
CD11b or Lin-DR-CD14-CD11b cells are refractory to alemtu-
zumab toxicity. This novel observation is of interest as IMSCs can
induce T cell tolerance and thus have the potential to control
GVHD. Critically, alemtuzumab purging of a hematopoietic stem
cell products has no effect on CD34 cell numbers and their
(CFU-c) as assessed in vitro.
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COMPARISON OF CELL DOSE AND OUTCOME FOR CORD BLOOD
TRANSPLANTATION (CBT) SOURCED FROM PLASMA DEPLETED (PD)
VERSUS RED CELL DEPLETED (RD) CORD BLOOD INVENTORIES
Wang, B.1, Tsukahara, E.1, Wu, T.1, Chow, T.1, Lin, A.2,
Gjertson, D.3, Petz, L.1, Chow, R.1,2,4 1StemCyte International Cord
Blood Center, Arcadia, CA; 2StemCyte Taiwan National Cord Blood
Center, Linkou, Taiwan; 3UCLA School of Public Health, Los Angeles,
CA; 4StemCyte Research Institute, Arcadia, CA.
To discern whether cord blood processing inﬂuences cord blood
bank (CBB) inventory cell dose and CBT outcome, we (1) per-
formed a large scale cell dose comparison of the NMDP CBBs that
practice red cell depletion (RD) versus plasma depletion (PD), (2)
performed an analysis comparing RD CBT results from an Insti-
tute of Medicine (IOM) study to audited outcome from a PD cord
blood (CB) inventory, and (3) searched the literature for outcome
of CBBs that practice PD and RD processing. Two of the CBBs in
the NMDP network practice PD processing (n10,912 CB)
whereas all others practice RD (n38,819 CB). PD processing
results in less than 1% cell loss in the discarded fraction (excluding
testing and archival samples), and various studies have reported
different recovery rates for RD; however, no data exist for a
rigorous comparison of actual inventories. Using data from
NMDP’s Cord Blood Bank Performance Report (6/30/06), the
percentage of high cell dose units among the two types of CBBs
were compared. Table 1A shows the proportion of CB with high
TNC counts was signiﬁcantly higher for PD CBU at all three
levels (p 0.0001; test for difference in proportions). To our
knowledge, this is the largest cell dose comparison of cord blood
banks.
The IOM conducted a study that analyzed the outcome of 3 large
CB inventories in order to ﬁnd determinants of engraftment and
patient survival (Gibbons 2005). The IOM study used RD CB. All
205 patients transplanted with PD CB through 5/06 with survival
and/or engraftment data were divided into three groups - alive,
dead, and engraftment failure - which were then compared to the
755 transplants from the IOM study using identical methodologies
(aliveengrafted & alive, deadengrafted & dead, and engraft-
ment failurenever engrafted). Table 1B summarizes the propor-
tion of patients in each category and chi-square test of homoge-
neity yielded a p-value of 0.002, suggesting that the PD CBT had
a signiﬁcantly higher proportion of survivors and lower proportion
of engraftment failures.
Various cord blood bank studies from the literature were also
summarized, which showed that transplants using PD CB may
have higher cell doses than those using RD CB. Moreover, various
RD CB inventories appeared to have similar outcome, which may
be different from transplants using PD CB inventories though
patient and disease proﬁles appear to match.
Cell Dose & Outcome Comparison Between PD & RD CB
Inventories
Table 1A NMDP PD CBB NMDP RD CBB
Test
for
Difference
CBU with
TNC
# & % of PD CB # & % of RD CB in Proportions
>125 107 3,772 (35%) 8,172 (21%) p < 0.0001
>150 107 2,157 (20%) 3,871 (10%) p < 0.0001
>200 107 703 (6%) 822 (2%) p < 0.0001
Table 1B # & % Alive # & % Dead
# & % Engraftment
Failure
PD CB 116(56.6%) 47(22.9%) 42(20.5%)
IOM CB 323(42.8%) 214(28.3%) 218(28.9%)
HEMATOPOIESIS/MESENCHYMAL CELLS
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TRANSPLANTATION OF VASCULAR ENDOTHELIAL CELLS MEDIATES
THE HEMATOPOIETIC RECOVERY AND SURVIVAL OF IRRADIATED MICE
Muramoto, G.G.1, Himburg, H.1, Salter, A.1, Meadows, S.1, Chen, B.1,
Rickman, D.1, Chao, N.J.1, Chute, J.P.1 1Duke University Medical
Center, Durham, NC.
During embryogenesis, Flk-1 endothelial precursors contrib-
ute critically to the deﬁnitive onset of hematopoiesis. Adult sources
of endothelial cells have also been shown to support the expansion
of hematopoietic stem cells in vitro. However, the in vivo contri-
bution of vascular endothelial cells to adult hematopoiesis has been
less well characterized. In this study, we sought to determine
whether transplantation of primary endothelial cells could enhance
the hematopoietic recovery and survival of lethally irradiated mice.
C57BL/6J mice were given sublethal (700 cGy) or lethal (1050
cGy) irradiation and subsequently transplanted with murine brain-
derived ECs (MBECs) or fetal blood-derived ECs (FBECs) for 5
days. Mice transplanted with MBECs alone demonstrated acceler-
ated BM cellular recovery, radioprotection of BM c-kitsca-1-lin-
progenitors and enhanced regeneration of c-kitsca-1lin-(KSL)
stem/progenitor cells following irradiation compared to controls.
MBEC transplantation also facilitated the recovery of circulating
white blood cells and platelet counts following radiation exposure.
Remarkably, 57% of mice transplanted with MBECs survived
long-term (60 days) following 1050 cGy irradiation, which was
100% lethal in control mice. Irradiated mice that were trans-
planted with FBECs also showed signiﬁcantly increased survival,
although these animals did not survive long-term. Conversely,
transplantation with mesenchymal stem cells (MSCs) had no im-
pact on the survival of irradiated mice, suggesting that an endo-
thelial cell-speciﬁc activity accounted for the observed effects.
These data suggest that vascular endothelial cells can mediate
hematopoietic recovery following myeloablative injury and that
transplantation of endothelial cells alone can improve the survival
of lethally irradiated animals.
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MESENCHYMAL STEM CELLS ARE EFFECTIVE AT PREVENTING BUT
NOT AT TREATING GVJD
Tisato, V.1, Naresh, K.2, Navarrete, C.3, Dazzi, F.1 1Departmento of
Haematology - Imperial College, London, United Kingdom; 2Depart-
ment of Pathology - Imperial College, London, United Kingdom; 3Na-
tional Blood Service, London, United Kingdom.
Mesenchymal stem cells (MSC) are progenitor cells of stromal
origin which can differentiate into multiple lineages. MSC also
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